TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 62; no. 13; pp. 3587 - 3591
Main Authors SINCLAIR, Colleen S, ADEM, Camilo, SLEZAK, Jeffrey, FREDERICKSEN, Zach, INGLE, James N, HARTMANN, Lynn, JENKINS, Robert B, COUCH, Fergus J, NADERI, Ali, SODERBERG, Cheryl L, JOHNSON, Michele, KANGJIAN WU, WADUM, Linda, COUCH, Vicki L, SELLERS, Thomas A, SCHAID, Daniel
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.07.2002
Subjects
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Female
Gene Amplification
Genes, BRCA1
Genes, BRCA2
Gynecology. Andrology. Obstetrics
Humans
In Situ Hybridization, Fluorescence
Mammary gland diseases
Medical sciences
Middle Aged
Mutation
Neoplasm Staging
T-Box Domain Proteins - genetics
Tumors
Human
Genetic gain
Long arm
Gene overexpression
Malignant tumor
Gene expression
Mammary gland diseases
Gene amplification
Chromosome E17
Female
Mammary gland
Mutation
Onc gene
Tumor suppressor gene
Online AccessGet full text

Cover

More Information
Summary:The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRCA1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0008-5472
1538-7445